Results 11 to 20 of about 57 (45)

Role of serotonin in body weight, insulin secretion and glycaemic control. [PDF]

J Neuroendocrinol, 2021
Abstract Obesity and type 2 diabetes are key healthcare challenges of the 21st century. Subsequent to its discovery in 1948, serotonin (5‐hydroxytryptamine; 5‐HT) has emerged as a principal modulator of energy homeostasis and body weight, prompting it to be a target of weight loss medications (eg, fenfluramine, D‐fenfluramine, fenfluramine‐phentermine ...
Georgescu T, Lyons D, Heisler LK.
europepmc   +2 more sources

Long-term safety and effectiveness of fenfluramine in children and adults with Dravet syndrome. [PDF]

Epilepsia
This graphical abstract provides an overview of the content from this open‐label extension study of fenfluramine use in patients with Dravet syndrome. Abstract Objective We analyzed the long‐term safety and effectiveness of fenfluramine (FFA) in patients with Dravet syndrome (DS) in an open‐label extension (OLE) study after participating in randomized ...
Scheffer IE, Nabbout R, Lagae L, Devinsky O, Auvin S, Thiele EA, Wirrell EC, Polster T, Specchio N, Pringsheim M, Imai K, Lock MD, Langlois M, Roper RZ, Lothe A, Sullivan J.   +15 more
europepmc   +2 more sources

Drosophila melanogaster as a rapid in vivo assay system for preclinical anti-seizure medication testing. [PDF]

Epilepsia Open
Abstract Epilepsy represents a significant medical challenge, with a third of patients failing to achieve seizure freedom despite the use of multiple different anti‐seizure medications (ASM). Drug resistance is common in genetically caused epilepsies. Patients are faced with repeated, long‐lasting, and frequently frustrating drug testing, necessitating
Töfflinger EV, Makridis KL, Heim MM, Owald D, Kaindl AM.   +4 more
europepmc   +2 more sources

Practical considerations for the use of fenfluramine to manage patients with Dravet syndrome or Lennox-Gastaut syndrome in clinical practice. [PDF]

Epilepsia Open
This is a graphical representation of the abstract and article highlights. Abstract Fenfluramine (FFA), an antiseizure medication (ASM) with serotonergic and sigma‐1 receptor activity, is used to manage patients with developmental and epileptic encephalopathies (DEEs).
Wirrell EC, Lagae L, Scheffer IE, Cross JH, Specchio N, Strzelczyk A.   +5 more
europepmc   +2 more sources

The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression. [PDF]

Clin Pharmacol Ther
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Le GH, Wong S, Johnson DE, Orsini DK, Zheng YJ, Teopiz KM, Dri CE, Rosenblat JD, McIntyre RS.   +8 more
europepmc   +2 more sources

Fenfluramine treatment in pediatric patients with Dravet syndrome reduces seizure burden and overall healthcare costs: A retrospective and observational real-world study. [PDF]

Epilepsia Open
Abstract Objectives Dravet syndrome is a developmental and epileptic encephalopathy characterized by early onset epilepsy with multiple seizure types often intractable to treatment. Randomized clinical trials have demonstrated how treatment with fenfluramine significantly reduces seizure frequency in patients with Dravet syndrome. The study aims to (1)
Gjerulfsen CE, Nikanorova M, Olofsson K, Johannessen Landmark C, Rubboli G, Møller RS.   +5 more
europepmc   +2 more sources

Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis. [PDF]

Epilepsia Open
Abstract Objectives Stiripentol, fenfluramine, and cannabidiol are licensed add‐on therapies to treat seizures in Dravet Syndrome (DS). There are no direct or indirect comparisons assessing their full licensed dose regimens, across different jurisdictions, as first‐line add‐on therapies in DS.
Guerrini R, Chiron C, Vandame D, Linley W, Toward T.   +4 more
europepmc   +2 more sources

Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo‐controlled clinical trial

Epilepsia, Volume 64, Issue 10, Page 2653-2666, October 2023., 2023
Abstract Objective This study was undertaken to assess the safety and efficacy of fenfluramine in the treatment of convulsive seizures in patients with Dravet syndrome. Methods This multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, phase 3 clinical trial enrolled patients with Dravet syndrome, aged 2–18 years with poorly ...
Joseph Sullivan, Lieven Lagae, J. Helen Cross, Orrin Devinsky, Renzo Guerrini, Kelly G. Knupp, Linda Laux, Marina Nikanorova, Tilman Polster, Dinesh Talwar, Berten Ceulemans, Rima Nabbout, Gail M. Farfel, Bradley S. Galer, Arnold R. Gammaitoni, Michael Lock, Anupam Agarwal, Ingrid E. Scheffer, the FAiRE DS Study Group, Deepak Gill, Kate Riney, Ingrid Scheffer, Berten Ceulemans, Jeffrey Buchhalter, Lionel Carmant, Mary Connolly, Marina Nikanorova, Rima Nabbout, Stephane Auvin, Claude Cances, Frederic Villega, Audrey Riquet, Dorethee Ville, Nathalie Villeneuve, Patrick Berquin, Ulrich Brandl, Julia Jacobs‐LeVan, Thomas Mayer, Axel Panzer, Tilman Polster, Milka Pringsheim, Ulrich Stephani, Markus Wolff, Domenica Battaglia, Francesca Beccaria, Francesca Darra, Tiziana Granata, Renzo Guerrini, Antonio Romeo, Pasquale Striano, Federico Vigevano, Antonio Gil‐Nagel, Victoria San Antonio, Rocio Sanchez‐Carpintero, J. Helen Cross, Archana Desurkar, Elaine Hughes, Anand Iyer, Sunny Philip, Sameer Zuberi, Gregory Sharp, Frank Berenson, Orrin Devinsky, Kelly Knupp, Linda Laux, Eric Marsh, Mark Nespeca, Ian Miller, Robert Nahouraii, Juliann Paolicchi, Steven Phillips, Michael Scott Perry, Annapurna Poduri, Ben Renfroe, Russell Saneto, Asim Shahid, Douglas Smith, Marcio Sotero de Menezes, Joseph Sullivan, Matthew Sweney, Dinesh Talwar, Elizabeth Thiele, James Wheless, Angus Wilfong, Elaine Wirrell, Mary Zupanc   +85 more
wiley   +1 more source

New insights into the early mechanisms of epileptogenesis in a zebrafish model of Dravet syndrome

Epilepsia, Volume 61, Issue 3, Page 549-560, March 2020., 2020
Abstract Objective To pinpoint the earliest cellular defects underlying seizure onset (epileptogenic period) during perinatal brain development in a new zebrafish model of Dravet syndrome (DS) and to investigate potential disease‐modifying activity of the 5HT2 receptor agonist fenfluramine.
Ettore Tiraboschi, Silvia Martina, Wietske van der Ent, Kamil Grzyb, Kinga Gawel, Maria Lorena Cordero‐Maldonado, Suresh Kumar Poovathingal, Sarah Heintz, Somisetty Venkata Satheesh, Jarle Brattespe, Ju Xu, Maximiliano Suster, Alexander Skupin, Camila V. Esguerra   +13 more
wiley   +1 more source

Effect of Hepatic Impairment on the Pharmacokinetics of Fenfluramine and Norfenfluramine

The Journal of Clinical Pharmacology, Volume 64, Issue 7, Page 887-898, July 2024.
Abstract Fenfluramine (Fintepla®) is approved for the treatment of seizures associated with the rare epileptic encephalopathies Dravet syndrome and Lennox–Gastaut syndrome. Fenfluramine is extensively metabolized; thus, patients with hepatic impairment (HI) might experience changes in exposure to fenfluramine or its metabolites.
Aravind Mittur, Ryan Madanick, Melanie Langlois, Brooks Boyd   +3 more
wiley   +1 more source